7 days 30 days All time Recent Popular
Every time I see tweets like these I think about the tech people I've met & the $500 Lanvins so many wear. Or the $1100 Owen kicks some of the CEO's wear. The shoes look like Converse but they cost like Gucci. Some cost more. They wear designer, just not the ones you know


The other thing a lot of them do? They have bespoke casual wear. So handmade t-shirts. Custom fit track suits. Hoodies that are designed specifically for them. Mostly a very specific kind of new money wears well known labels, but they all wear designer. Stop blaming clothes

The real difference between rich people and poor people is generational wealth. That's it. Your parents can afford to pay for your education. Leg up. You inherit property? Leg up. Your family can invest 6 figures in your start up? Leg up. Rich people in America have help.

They have help from before birth tbh. Because their grandparents contribute to college funds. They buy rental property & gift it to their grandkids. They had more than enough money for their own expenses so they left money. And the parents of rich people? Rich too.

It's not the Gucci belt that's a barrier to economic stability for people now. It's not having a time machine to undo the impact of 5 generations of poverty. Even the best "rags to riches, by my bootstraps" stories have generational wealth hidden in them. Usually a friend's.
$ARPO Thread: Raz P2b glaucoma readout Dec 15 to Jan 15, assigning 90% POS, potential 3 to 5x, with (likely) partnership 1H21. Glaucoma dead for Big Pharma unless there’s a brand new MOA or pathway being targeted. Here we have both…a new MOA (Tie2) and a new location (SC)

https://t.co/zsc2eBVI4e Tons of great preclinical work on TIE2 MOA showing clear correlation to SC integrity, adult-onset glaucoma, and disease-modifying effects. See mosaic if interested


What do KOL's think of the new MOA: Special session held at ARVO 2019 to discuss Tie2 for Glaucoma. $ARPO then completed a closely watched P1b with a topical formulation. Now, a P2b trial in 195 pts enrolled within 3 mos, a month ahead of schedule, in the middle of a pandemic.

SOC is PG (-7 mm Hg IOP) +/- adjunct (-1 to -1.5 mm delta). Best efficacy adjunct is Rocklatan (-1.5), but AE profile: hyperemia (60 vs 15%), pruritus (8 vs 2%) site pain (20 vs 7%) vs PG , + other AE’s not seen with PG: 10% conjunctival hemorrhage, 15% verticillata. Almost DOA

But, sells $80 to $100M/yr US (same as $ARPO MC ha!). Every 0.3 mm reduction critical towards delaying vision loss. Rocklatan MOA was projected to make it a $1B drug, until AE profile (& payor delays) killed launch. $ARPO thesis: Raz efficacy >/= Rocklatan, without AE baggage.
SUBEX 💻

CMP:30

Technically given breakout at 19 only. I am posting this note after I got my own conviction.

Dont buy at one go, buy on DIP’s


-Positive points to be considered

SUBEX plans to foray into emerging verticals like Fintech&E-commerce by expanding digital trust business beyond its core area of Telecom sector

SUBEX is literally Zero /negligible debt company,hence it can focus on growth in new verticals

SUBEX main advantage is 75% of telecom companies are their clients

SUBEX now focusing on internet of things (IOT) , security and analytics and management expecting 140n to 200 crores additional revenue from new verticals

1/5 th of the global teleco’s tariff goes through company,counts British Telecom,Airtel,JIO,VI,T-Mobile,AT & T,Orannge and Swisscom and etc.

SUBEX has increased its employees by 15%

Key possitive factor for SUBEX is new and promising Management

SUBEX has massive leverage with the existing teleco customers thhey can take major advantage out of it to enhance their business in new areas such as IOT security,FinTech,Digital Trust, Cyber security & 5G.
At a time when Buffett is being criticised for his style, again, I can't help but admire the investor & the person. Can't help but want to be more like him.

"Buy a company because you want to own it, not because you want the stock to go up."

Some excerpts:

👇


"Buy stocks for simple reasons, not torturous & sophisticated ones".

Eventually the thesis for a good investment boils down to 2-3 simple points. You have to do a lot of work to figure out what those are & why.

2/


Even Buffett has struggled with & changed his exit decisions. This I believe is a much tougher problem than the buy decision.

3/


1969 article: He has made a fortune and is no longer motivated to count boxcars and read statistical manuals. He comes close to the truth when he says: “You shouldn’t be doing at 60 what you did at 20.”

90 & still counting box-cars.

4/


He attributes his problem to a market that no longer lends itself to his kind of analysis, where real values are hard to find. - 1969

It has been 50 years since we are debating whether the market values "this kind of analysis".

"This kind of analysis" is all that there is.

5/